PDCD1 and melanoma: For example, in a phase Ib clinical trial for advanced melanoma patients who are unresponsive or have failed PD-1 monotherapy, the TLR9 agonist Vidutolimod induces and attracts anti-tumor T cells by triggering a strong IFN response, thereby reversing PD-1 blockade resistance.